This site is intended for Healthcare Professionals only

New ticagrelor dose

Clinical bookmark icon off

New ticagrelor dose

The EC has granted marketing authorisation for a 60mg dose of ticagrelor (Brilique) for patients who suffered a heart attack at least one year previously and who are considered at high risk of another atherothrombotic event. The new dose may be started as continuation therapy after one year’s treatment with ticagrelor 90mg and aspirin or another dual antiplatelet regimen.

Copy Link copy link button

Clinical

Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.

Share: